Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
Holding IMVT?
Track your performance easily
Earnings Data
Report Date
Feb 12, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.75Last Year’s EPS
-0.29Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Jun 29, 2020
|% Change Since: -24.25%
|Next Earnings Date:Feb 14, 2020
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in Immunovant's development programs, particularly for IMVT-1402, with promising data in Graves' disease and a strategic approach in rheumatoid arthritis. However, the company faces challenges in the thyroid eye disease program's enrollment and efficacy demonstration for FcRn inhibitors. Overall, the sentiment leans towards optimism due to strategic progress despite some hurdles.Company Guidance
During the Q2 2025 earnings call, Immunovant provided substantial guidance on their development progress, particularly highlighting their lead asset, IMVT-1402. The company has cleared five Investigational New Drug (IND) applications ahead of schedule, aiming to launch 10 indications by March 2026, with four to five potentially registrational trials starting by March 2025. They expect data readouts from their myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) programs, which are fully enrolled, in the upcoming months. Immunovant also shared promising data on Graves' disease, where IMVT-1402 demonstrated significant IgG suppression, correlating with improved clinical outcomes. The company is also exploring an innovative trial design for difficult-to-treat rheumatoid arthritis, targeting patients with high ACPA levels to validate the efficacy of deeper IgG reduction, aiming for a high impact in this high unmet need population.Significant Progress with IMVT-1402 Development
In 2024, Immunovant cleared 5 INDs across a range of therapeutic areas, ahead of their schedule, and is on track to launch 10 indications by March 2026.
Promising Data on Graves' Disease
Recent data shows a 60% ATD-free response rate in patients whose IgG was lowered by 70% or more, indicating strong potential for IMVT-1402 in treating Graves' disease.
Introduction of Rheumatoid Arthritis Program
The rheumatoid arthritis program targets difficult-to-treat patients with a biomarker-driven strategy, leveraging prior proof-of-principle data with FcRn inhibitors.
Open-Label Trial Design for Rheumatoid Arthritis
The innovative trial design offers an open-label lead-in period, enhancing patient enrollment and providing early data catalysts.
---
IMVT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IMVT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $31.42 | $29.93 | -4.74% |
| Aug 06, 2024 | $27.85 | $26.98 | -3.12% |
| May 29, 2024 | $29.57 | $26.41 | -10.69% |
| Feb 12, 2024 | $35.50 | $36.69 | +3.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Immunovant (IMVT) report earnings?
Immunovant (IMVT) is schdueled to report earning on Feb 12, 2025, TBA Not Confirmed.
What is Immunovant (IMVT) earnings time?
Immunovant (IMVT) earnings time is at Feb 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IMVT EPS forecast?
IMVT EPS forecast for the fiscal quarter 2025 (Q3) is -0.75.
---